Home › Activist investors › Kent Lake Capital
Campaign activist. Positions and campaigns from Kent Lake Capital’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Universal Electronics Inc | 7.4%990,870 shares | Schedule 13D/A, filed Aug 27, 2025 | Mar 27, 2025 | Decreased Aug 27, 2025 | ▼ 1.20 pts | — | Seeks changes or engagement |
| Quanterix Corp. | 2.14%1,001,000 shares | 13F, quarter ended Sep 30, 2025filed Nov 14, 2025; % of shares outstanding as of Nov 4, 2025 | Nov 14, 2022 | Decreased Nov 14, 2025 | ▼ 3.78 pts | — | 13F: none stated |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“Item 4 is hereby amended to add the following: On May 2, 2025, the Reporting Persons entered into a letter agreement (the "Cooperation Agreement") with the Issuer, pursuant to which the Issuer agreed to appoint Michael D. Burger as a Class II director with a term expiring at the Issuer's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). Mr. Burger will be appointed to the Operations Committee of the Board”
Item 4 in the Schedule 13D/A filed Aug 27, 2025; this amendment did not restate Item 4, so the text is from the filing of May 5, 2025.
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Inogen Inc | Settled (agreement with the company) | Apr 6, 2026 | Apr 6, 2026 | — | latest (1) | — |
| Quanterix CorpBoard seats | Settled (agreement with the company) | Aug 4, 2025 | Feb 13, 2025 | Proxy contest filed | latest (19) | — |
| Universal Electronics Inc | Settled (agreement with the company) | May 5, 2025 | Mar 27, 2025 | — | latest (3) | — |
| Veradigm Inc.Board seats | Settled — 2 board seats | Feb 20, 2025 | May 16, 2024 | — | latest (3) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Veradigm Inc. | 5.0% | Schedule 13D, filed May 16, 2024 | Not in the 13F for the quarter ended Jun 30, 2024 | Aug 14, 2024 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Inogen Inc | Settlement | agreement with the company | Apr 6, 2026 | Apr 6, 2026 |
| Quanterix Corp | Settlement | agreement with the company | Aug 4, 2025 | Feb 13, 2025 |
| Universal Electronics Inc | Settlement | agreement with the company | May 5, 2025 | Mar 27, 2025 |
| Veradigm Inc. | Settlement with board seats | 2 board seats | Mar 18, 2025 | May 16, 2024 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 2 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“…andstill provisions prohibiting them from, among other things, (i) soliciting proxies, (ii) advising or knowingly encouraging any person with respect to the disposition of any securities of the Company, subject to limited exceptions, (iii) acquiring, in the aggregate, beneficial ownership of more than 4.99% of the outstanding shares of Voting Securities (as defined in the Cooperation Agreement) and (iv) taking actions to change or influence the Board, management or the direct…” 8-K, Apr 6, 2026
“In addition, Kent Lake has agreed to customary standstill and voting commitments until thirty days prior to the nomination deadline for Quanterix’s 2027 Annual Meeting.” 8-K, Aug 4, 2025
“During the term of the Cooperation Agreement, the Investor Parties have agreed to vote all shares of Common Stock beneficially owned by them at all meetings of the Company’s stockholders in accordance with the Board’s recommendations, except that the Investor Parties may vote in their discretion on Extraordinary Transactions (as defined in the Cooperation Agreement), proposals involving the implementation of takeover defenses not in existence as of the date of the Cooperation…” 8-K, May 5, 2025
“EX-99.1 4 d877339dex991.htm EX-99.1 Exhibit 99.1 Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to succeed Greg Garrison as Chairman CHICAGO – March 18, 2025 – Veradigm Inc. (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the “Board”) appointed two new indepe…” 8-K, Mar 18, 2025
“EX-99.1 4 d877339dex991.htm EX-99.1 Exhibit 99.1 Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to succeed Greg Garrison as Chairman CHICAGO – March 18, 2025 – Veradigm Inc. (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the “Board”) appointed two new indepe…” 8-K, Mar 18, 2025
“EX-99.1 3 d916839dex991.htm EX-99.1 Exhibit 99.1 Veradigm Announces Board Expansion and Changes Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors CHICAGO – February 20, 2025 – Veradigm ® (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the “Agreement”) with Kent Lake PR LLC (“Kent Lake”).” 8-K, Feb 20, 2025